SK16552002A3 - Stála, biologicky zlúčiteľná, dobre znášateľná mikroemulzia voda v oleji a jej použitie - Google Patents
Stála, biologicky zlúčiteľná, dobre znášateľná mikroemulzia voda v oleji a jej použitie Download PDFInfo
- Publication number
- SK16552002A3 SK16552002A3 SK1655-2002A SK16552002A SK16552002A3 SK 16552002 A3 SK16552002 A3 SK 16552002A3 SK 16552002 A SK16552002 A SK 16552002A SK 16552002 A3 SK16552002 A3 SK 16552002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- microemulsion
- biologically active
- surfactant
- active compound
- days
- Prior art date
Links
- 238000007911 parenteral administration Methods 0.000 title claims abstract description 10
- 150000002433 hydrophilic molecules Chemical class 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 6
- 238000013268 sustained release Methods 0.000 title abstract description 3
- 239000012730 sustained-release form Substances 0.000 title abstract description 3
- 239000004530 micro-emulsion Substances 0.000 claims abstract description 122
- 238000001212 derivatisation Methods 0.000 claims abstract description 5
- 239000004094 surface-active agent Substances 0.000 claims description 49
- 108010000817 Leuprolide Proteins 0.000 claims description 32
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 31
- 229960004338 leuprorelin Drugs 0.000 claims description 31
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 24
- 108010016076 Octreotide Proteins 0.000 claims description 22
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000003921 oil Substances 0.000 claims description 19
- 239000012071 phase Substances 0.000 claims description 19
- 238000013270 controlled release Methods 0.000 claims description 18
- 239000000194 fatty acid Substances 0.000 claims description 13
- 239000008346 aqueous phase Substances 0.000 claims description 12
- 229960003604 testosterone Drugs 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 229960002700 octreotide Drugs 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 150000001298 alcohols Chemical class 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 150000001242 acetic acid derivatives Chemical class 0.000 claims description 5
- 108700008462 cetrorelix Proteins 0.000 claims description 5
- 229960003230 cetrorelix Drugs 0.000 claims description 5
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 108700020746 histrelin Proteins 0.000 claims description 5
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 claims description 5
- 229960002193 histrelin Drugs 0.000 claims description 5
- 230000002209 hydrophobic effect Effects 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 230000008961 swelling Effects 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- 108010069236 Goserelin Proteins 0.000 claims description 4
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 4
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229960002913 goserelin Drugs 0.000 claims description 4
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 4
- 230000002085 persistent effect Effects 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 4
- 229960004824 triptorelin Drugs 0.000 claims description 4
- 230000036269 ulceration Effects 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 3
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 3
- 108010056088 Somatostatin Proteins 0.000 claims description 3
- 102000005157 Somatostatin Human genes 0.000 claims description 3
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 3
- 229940022663 acetate Drugs 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 108010021336 lanreotide Proteins 0.000 claims description 3
- 150000002482 oligosaccharides Polymers 0.000 claims description 3
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
- 229960000553 somatostatin Drugs 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 108010051696 Growth Hormone Proteins 0.000 claims description 2
- 108010021717 Nafarelin Proteins 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 229960002437 lanreotide Drugs 0.000 claims description 2
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 238000010171 animal model Methods 0.000 claims 1
- 150000001735 carboxylic acids Chemical group 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229960002333 nafarelin Drugs 0.000 claims 1
- 239000000813 peptide hormone Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 34
- 239000004480 active ingredient Substances 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 13
- 239000000203 mixture Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 17
- 238000009472 formulation Methods 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 14
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 11
- 229940093471 ethyl oleate Drugs 0.000 description 11
- 229960001494 octreotide acetate Drugs 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 9
- 239000004472 Lysine Substances 0.000 description 9
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 229960002446 octanoic acid Drugs 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 239000008347 soybean phospholipid Substances 0.000 description 7
- 239000008215 water for injection Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000008240 homogeneous mixture Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- -1 fatty acid esters Chemical class 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 239000012266 salt solution Substances 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000011886 postmortem examination Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- RUGAHXUZHWYHNG-NLGNTGLNSA-N acetic acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 RUGAHXUZHWYHNG-NLGNTGLNSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004309 nafarelin acetate Drugs 0.000 description 1
- DEQANNDTNATYII-RRCPSWKPSA-N octreotide Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](C(C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-RRCPSWKPSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000010587 phase diagram Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI001173A IT1318539B1 (it) | 2000-05-26 | 2000-05-26 | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| PCT/EP2001/005949 WO2001089479A2 (en) | 2000-05-26 | 2001-05-23 | Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK16552002A3 true SK16552002A3 (sk) | 2003-05-02 |
Family
ID=11445131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1655-2002A SK16552002A3 (sk) | 2000-05-26 | 2001-05-23 | Stála, biologicky zlúčiteľná, dobre znášateľná mikroemulzia voda v oleji a jej použitie |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7157099B2 (xx) |
| EP (1) | EP1283700B1 (xx) |
| JP (1) | JP4954423B2 (xx) |
| KR (1) | KR100802625B1 (xx) |
| CN (1) | CN100479856C (xx) |
| AT (1) | ATE321533T1 (xx) |
| AU (2) | AU8178601A (xx) |
| BR (1) | BRPI0111016B8 (xx) |
| CA (1) | CA2409854C (xx) |
| CY (1) | CY1105262T1 (xx) |
| CZ (1) | CZ302059B6 (xx) |
| DE (1) | DE60118395T2 (xx) |
| DK (1) | DK1283700T3 (xx) |
| ES (1) | ES2257428T3 (xx) |
| HR (1) | HRP20020929A2 (xx) |
| HU (1) | HU228926B1 (xx) |
| IL (1) | IL153011A0 (xx) |
| IT (1) | IT1318539B1 (xx) |
| MX (1) | MXPA02011539A (xx) |
| NO (1) | NO334880B1 (xx) |
| PL (1) | PL203354B1 (xx) |
| PT (1) | PT1283700E (xx) |
| RU (1) | RU2272615C2 (xx) |
| SI (1) | SI1283700T1 (xx) |
| SK (1) | SK16552002A3 (xx) |
| WO (1) | WO2001089479A2 (xx) |
| YU (1) | YU88202A (xx) |
| ZA (1) | ZA200209520B (xx) |
Families Citing this family (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| EP1787658B1 (en) | 2005-11-10 | 2012-03-14 | CHEMI S.p.A. | Sustained release formulations of somatostatin analogue inhibitors of growth hormone |
| MX2008012678A (es) | 2006-04-07 | 2008-12-17 | Merrion Res Iii Ltd | Forma de dosis oral solida que contiene un mejorador. |
| KR100816065B1 (ko) * | 2006-11-27 | 2008-03-24 | 동국제약 주식회사 | 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐 |
| RU2362544C2 (ru) * | 2007-04-09 | 2009-07-27 | Закрытое акционерное общество "Санкт-Петербургский институт фармации" | Наноэмульсия с биологически активными веществами |
| CN105475802A (zh) * | 2007-10-04 | 2016-04-13 | 因斯蒂尔医学技术有限公司 | 用于配制和无菌充注液体产品的设备和方法 |
| KR20110007242A (ko) | 2008-05-07 | 2011-01-21 | 메리온 리서치 Ⅲ 리미티드 | 펩티드 조성물 및 그의 제조 방법 |
| CA2786181C (en) | 2010-01-13 | 2017-12-12 | Ipsen Pharma S.A.S. | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
| US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
| EP2555778A4 (en) | 2010-04-06 | 2014-05-21 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING CD274 / PD-L1 GENE EXPRESSION |
| CA2801066C (en) | 2010-06-02 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
| EP2425814B1 (en) | 2010-09-03 | 2013-06-19 | Novagali Pharma S.A. | A water-in-oil type emulsion for treating a disease of the eye |
| AU2011298298B2 (en) | 2010-09-03 | 2016-04-21 | Santen Sas | A water-in-oil type emulsion for treating a disease of the eye |
| US9107822B2 (en) | 2010-09-03 | 2015-08-18 | Santen Sas | Water-in oil type emulsion for treating a disease of the eye |
| WO2012078967A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (epo) production |
| EP2648763A4 (en) | 2010-12-10 | 2014-05-14 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A |
| CN103476419A (zh) | 2011-01-07 | 2013-12-25 | 梅里翁第三研究有限公司 | 口服投药的含铁药物组合物 |
| CN118792301A (zh) | 2011-03-29 | 2024-10-18 | 阿尔尼拉姆医药品有限公司 | 用于抑制tmprss6基因表达的组合物和方法 |
| WO2012166903A1 (en) | 2011-06-02 | 2012-12-06 | President And Fellows Of Harvard College | Methods and uses for ex vivo tissue culture systems |
| KR102395085B1 (ko) | 2011-06-21 | 2022-05-09 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법 |
| US20140275211A1 (en) | 2011-06-21 | 2014-09-18 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
| EP3597750B1 (en) | 2011-06-23 | 2022-05-04 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
| AU2012275841A1 (en) | 2011-06-27 | 2014-01-16 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
| EP2739735A2 (en) | 2011-08-01 | 2014-06-11 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
| CN102552138A (zh) * | 2012-02-28 | 2012-07-11 | 大连医科大学 | 口服羟丝肽w/o微乳制剂及其制备方法 |
| CN102552187B (zh) * | 2012-02-28 | 2015-10-28 | 大连医科大学 | 口服羟丝肽纳米粒及其制备方法 |
| JP6182165B2 (ja) * | 2012-03-05 | 2017-08-16 | アーチャー−ダニエルズ−ミッドランド カンパニー | マイクロエマルジョンおよび送達系としてのその使用 |
| US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| RS56783B9 (sr) | 2012-12-05 | 2021-12-31 | Alnylam Pharmaceuticals Inc | Sastavi pcsk9 irnk i postupci njihovih primena |
| CA2904654C (en) | 2013-03-14 | 2023-12-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| EP2978446B1 (en) | 2013-03-27 | 2020-03-04 | The General Hospital Corporation | Anti-cd33 antibody for use in treating alzheimer's disease |
| WO2014182661A2 (en) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages and methods for delivering lipid formulated nucleic acid molecules |
| HUE038146T2 (hu) | 2013-05-22 | 2018-09-28 | Alnylam Pharmaceuticals Inc | Serpina1 IRNS készítmények és eljárások alkalmazásukra |
| BR112015029276B1 (pt) | 2013-05-22 | 2022-07-12 | Alnylam Pharmaceuticals, Inc | Agente de irna fita dupla capaz de inibir a expressão de tmprss6, composição farmacêutica e uso dos mesmos |
| WO2014199352A2 (en) | 2013-06-14 | 2014-12-18 | Invictus Oncology Pvt. Ltd. | Lipid-based platinum-n-heterocyclic carbene compounds and nanoparticles |
| EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| EP2832361A1 (en) * | 2013-07-29 | 2015-02-04 | Ipsen Pharma S.A.S. | Aqueous sustained release compositions of LHRH analogs |
| EP3052626A1 (en) | 2013-10-02 | 2016-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| UA124961C2 (uk) | 2013-10-04 | 2021-12-22 | Елнілем Фармасьютикалз, Інк. | ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1 |
| SG11201604692UA (en) | 2013-12-12 | 2016-07-28 | Alnylam Pharmaceuticals Inc | Complement component irna compositions and methods of use thereof |
| CN106103718B (zh) | 2014-02-11 | 2021-04-02 | 阿尔尼拉姆医药品有限公司 | 己酮糖激酶(KHK)iRNA组合物及其使用方法 |
| TW201607559A (zh) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | 治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物 |
| MX2016015126A (es) | 2014-05-22 | 2017-02-23 | Alnylam Pharmaceuticals Inc | Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas. |
| KR101686986B1 (ko) | 2014-07-28 | 2016-12-16 | 에스케이케미칼주식회사 | 류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
| EP3207138B1 (en) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
| EP3212794B1 (en) | 2014-10-30 | 2021-04-07 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
| JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| EP3797789B1 (en) | 2015-01-20 | 2024-08-21 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
| ES2975708T3 (es) | 2015-01-29 | 2024-07-12 | Novo Nordisk As | Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico |
| CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
| WO2016164746A1 (en) | 2015-04-08 | 2016-10-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| TWI723986B (zh) | 2015-04-13 | 2021-04-11 | 美商阿尼拉製藥公司 | 類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其用途方法 |
| CN108271386B (zh) | 2015-05-06 | 2022-07-15 | 阿尔尼拉姆医药品有限公司 | 因子XII(哈格曼因子)(F12)、激肽释放酶B、血浆(夫列契因子)1(KLKB1)和激肽原1(KNG1)iRNA组合物及其使用方法 |
| EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
| US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
| AU2016315584B2 (en) | 2015-09-02 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof |
| WO2017048620A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| WO2017048843A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
| US20180312534A1 (en) | 2015-10-16 | 2018-11-01 | Invictus Oncology Pvt. Ltd. | Fluorescent anticancer platinum drugs |
| RU2754188C2 (ru) | 2015-12-07 | 2021-08-30 | Джензим Корпорейшн | Способы и композиции для лечения ассоциированного с serpinc1 расстройства |
| JP2018536689A (ja) | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
| MA45295A (fr) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser |
| JP2019518028A (ja) | 2016-06-10 | 2019-06-27 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法 |
| TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| SG10201913552UA (en) | 2016-12-16 | 2020-03-30 | Alnylam Pharmaceuticals Inc | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions |
| AU2018301477A1 (en) | 2017-07-13 | 2020-02-27 | Alnylam Pharmaceuticals Inc. | Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof |
| EP3704252A1 (en) | 2017-11-01 | 2020-09-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| WO2019099610A1 (en) | 2017-11-16 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
| WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| KR20200110655A (ko) | 2017-12-18 | 2020-09-24 | 알닐람 파마슈티칼스 인코포레이티드 | 고이동성 그룹 박스-1 (hmgb1) irna 조성물 및 이의 사용 방법 |
| TW202020157A (zh) | 2018-08-16 | 2020-06-01 | 美商艾爾妮蘭製藥公司 | 用於抑制lect2基因表現之組合物及方法 |
| US20210332367A1 (en) | 2018-09-18 | 2021-10-28 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
| WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| US20220290152A1 (en) | 2019-09-03 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
| EP4051796A1 (en) | 2019-11-01 | 2022-09-07 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
| TW202132567A (zh) | 2019-11-01 | 2021-09-01 | 美商阿尼拉製藥公司 | 亨汀頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法 |
| KR20220115995A (ko) | 2019-12-13 | 2022-08-19 | 알닐람 파마슈티칼스 인코포레이티드 | 인간 염색체 ９ 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법 |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| JP2023514190A (ja) | 2020-02-10 | 2023-04-05 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Ｖｅｇｆ－ａ発現をサイレンシングするための組成物および方法 |
| WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
| EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
| EP4127168A1 (en) | 2020-03-26 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
| EP4127171A2 (en) | 2020-03-30 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
| WO2021207167A1 (en) | 2020-04-06 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing myoc expression |
| CN116134135A (zh) | 2020-04-07 | 2023-05-16 | 阿尔尼拉姆医药品有限公司 | 用于沉默scn9a表达的组合物和方法 |
| WO2021206917A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| EP4133077A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
| MX2022013525A (es) | 2020-04-27 | 2023-01-24 | Alnylam Pharmaceuticals Inc | Composiciones de agentes de ácido ribonucleico de interferencia (arni) de apolipoproteína e (apoe) y métodos de uso de las mismas. |
| EP4153746A1 (en) | 2020-05-21 | 2023-03-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
| EP4162050A1 (en) | 2020-06-09 | 2023-04-12 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
| EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
| EP4225917A1 (en) | 2020-10-05 | 2023-08-16 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
| WO2022087041A1 (en) | 2020-10-21 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
| EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
| WO2022119873A1 (en) | 2020-12-01 | 2022-06-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
| AU2022220704A1 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| CN117222739A (zh) | 2021-02-25 | 2023-12-12 | 阿尔尼拉姆医药品有限公司 | 朊病毒蛋白(prnp)irna组合物和其使用方法 |
| WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
| BR112023019981A2 (pt) | 2021-03-29 | 2023-12-12 | Alnylam Pharmaceuticals Inc | Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas |
| US20240180865A1 (en) * | 2021-04-08 | 2024-06-06 | Tionlab Therapeutics | Sustained-release lipid pre-concentrate |
| JP2024522068A (ja) | 2021-05-18 | 2024-06-11 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法 |
| AU2022283796A1 (en) | 2021-06-04 | 2023-11-09 | Alnylam Pharmaceuticals, Inc. | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| EP4373934A1 (en) | 2021-07-19 | 2024-05-29 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
| TW202334418A (zh) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | 杭丁頓（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法 |
| WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
| WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08505367A (ja) * | 1992-10-16 | 1996-06-11 | スミスクライン・ビーチャム・コーポレイション | 医薬用エマルジョン組成物 |
| SE512663C2 (sv) * | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| EP1023045A2 (en) * | 1997-10-24 | 2000-08-02 | Neorx Corporation | Delivery vehicles for bioactive agents and uses thereof |
-
2000
- 2000-05-26 IT IT2000MI001173A patent/IT1318539B1/it active
-
2001
- 2001-05-23 US US10/258,616 patent/US7157099B2/en not_active Expired - Lifetime
- 2001-05-23 MX MXPA02011539A patent/MXPA02011539A/es active IP Right Grant
- 2001-05-23 PL PL359601A patent/PL203354B1/pl unknown
- 2001-05-23 SI SI200130529T patent/SI1283700T1/sl unknown
- 2001-05-23 AT AT01960242T patent/ATE321533T1/de active
- 2001-05-23 JP JP2001585724A patent/JP4954423B2/ja not_active Expired - Lifetime
- 2001-05-23 AU AU8178601A patent/AU8178601A/xx active Pending
- 2001-05-23 BR BRPI0111016-0 patent/BRPI0111016B8/pt not_active IP Right Cessation
- 2001-05-23 PT PT01960242T patent/PT1283700E/pt unknown
- 2001-05-23 ES ES01960242T patent/ES2257428T3/es not_active Expired - Lifetime
- 2001-05-23 CN CNB018099254A patent/CN100479856C/zh not_active Expired - Lifetime
- 2001-05-23 DK DK01960242T patent/DK1283700T3/da active
- 2001-05-23 DE DE60118395T patent/DE60118395T2/de not_active Expired - Lifetime
- 2001-05-23 YU YU88202A patent/YU88202A/sh unknown
- 2001-05-23 RU RU2002135086/15A patent/RU2272615C2/ru active
- 2001-05-23 HU HU0301921A patent/HU228926B1/hu unknown
- 2001-05-23 CA CA2409854A patent/CA2409854C/en not_active Expired - Lifetime
- 2001-05-23 SK SK1655-2002A patent/SK16552002A3/sk unknown
- 2001-05-23 IL IL15301101A patent/IL153011A0/xx active IP Right Grant
- 2001-05-23 AU AU2001281786A patent/AU2001281786B8/en not_active Expired
- 2001-05-23 KR KR1020027015828A patent/KR100802625B1/ko active IP Right Grant
- 2001-05-23 EP EP01960242A patent/EP1283700B1/en not_active Expired - Lifetime
- 2001-05-23 WO PCT/EP2001/005949 patent/WO2001089479A2/en active IP Right Grant
- 2001-05-23 CZ CZ20023772A patent/CZ302059B6/cs not_active IP Right Cessation
-
2002
- 2002-11-22 NO NO20025621A patent/NO334880B1/no not_active IP Right Cessation
- 2002-11-22 HR HR20020929A patent/HRP20020929A2/xx not_active Application Discontinuation
- 2002-11-22 ZA ZA200209520A patent/ZA200209520B/en unknown
-
2006
- 2006-06-05 CY CY20061100724T patent/CY1105262T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK16552002A3 (sk) | Stála, biologicky zlúčiteľná, dobre znášateľná mikroemulzia voda v oleji a jej použitie | |
| AU2001281786A1 (en) | Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds | |
| EP1682091B1 (en) | Compositions of lipids and cationic peptides | |
| AU672441B2 (en) | Injectable lecithin gel | |
| CA2609810C (en) | Glp-1 analogue formulations | |
| EP2938332B1 (en) | Sustained-release lipid pre-concentrate of gnrh analogues and pharmaceutical composition comprising the same | |
| JP2008526934A (ja) | ＧｎＲＨ類似体製剤 | |
| EA035495B1 (ru) | Состав-предшественник, содержащий агонист рецепторов соматостатина, способ лечения путем его введения, его применение, предварительно заполненное устройство, содержащее его, и набор, содержащий указанное устройство | |
| KR20220002140A (ko) | GnRH 유도체를 포함하는 주사용 조성물 | |
| RU2827376C1 (ru) | ИНЪЕКЦИОННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНАЛОГ GnRH | |
| WO2001097778A2 (en) | Amphotericin b structured emulsion |